Assessment of change in the basic variants composition of trastuzumab during dilution in saline for administration

• Published in: European journal of pharmaceutics and biopharmaceutics 2024-06, Vol.199, p.114295-114295, Article 114295
• Main Authors: Gupta, Surbhi, Schöneich, Christian, Rathore, Anurag S.
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents, Immunological - administration & dosage; Antineoplastic Agents, Immunological - chemistry; Basic variants; Drug Stability; Humans; Hydrogen-Ion Concentration; Isomerization; Postproduction handling; Practical stability; Receptor, ErbB-2 - metabolism; Saline Solution - chemistry; Succinimide intermediate; Temperature; Trastuzumab - chemistry
• ISSN: 0939-6411; 1873-3441
• DOI: 10.1016/j.ejpb.2024.114295

[Display omitted] Postproduction handling of drug products during preparation or clinical use may affect the structure and efficacy of the drug and perhaps remain unnoticed. Since chemical modifications can impact the product's structure, stability, and biological activity, this study investigates the impact of elevated temperature and subtle shift in pH on the drug product post-dilution in saline. The mAb sample diluted in saline for administration was stressed at elevated temperature and slightly acidic pH condition. Extended stability studies were performed and monitored for size and charge heterogeneity. Size heterogeneity shows no significant changes, whereas charge heterogeneity shows an increase in basic variants and a reduction in main species. Further, basic variants were isolated and characterized to identify the type and site of chemical modification. Intact mass analysis and peptide mapping identify that the basic variants were attributed mainly to the isomerization of HC Asp102 into iso-Asp or its succinimide intermediate. Four basic variants were found to exhibit similar structural properties as the main and control samples. However, basic variants showed reduced binding affinity to HER2 receptor, while there was no significant difference in FcRn binding. The results indicate that modification in the HC Asp102, which is present in the CDR, affects antigen binding and thus can influence the potency of the drug product. Hence, with the conventional stability studies required to license the drug product, including in-use or extended stability studies to mimic the postproduction handling would be desirable.